$-0.02 EPS Expected for Enzo Biochem, Inc. (ENZ); Brooks Automation, Inc. (BRKS) Covered By 4 Bullish Analysts Last Week

December 8, 2017 - By Henry Gaston

Analysts expect Enzo Biochem, Inc. (NYSE:ENZ) to report $-0.02 EPS on December, 14.They anticipate $0.01 EPS change or 33.33% from last quarter’s $-0.03 EPS. The stock increased 2.59% or $0.24 during the last trading session, reaching $9.51. About 170,018 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since December 8, 2016 and is uptrending. It has outperformed by 27.62% the S&P500.

Among 6 analysts covering Brooks Automation (NASDAQ:BRKS), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Brooks Automation has $38 highest and $9.10 lowest target. $31.33’s average target is 31.14% above currents $23.89 stock price. Brooks Automation had 20 analyst reports since August 14, 2015 according to SRatingsIntel. B. Riley & Co maintained Brooks Automation, Inc. (NASDAQ:BRKS) rating on Thursday, February 4. B. Riley & Co has “Buy” rating and $16.50 target. On Friday, August 14 the stock rating was maintained by Citigroup with “Neutral”. Citigroup upgraded the shares of BRKS in report on Wednesday, October 12 to “Buy” rating. The firm has “Hold” rating given on Tuesday, January 3 by Stifel Nicolaus. B. Riley & Co maintained Brooks Automation, Inc. (NASDAQ:BRKS) on Thursday, August 3 with “Buy” rating. The firm earned “Underperform” rating on Tuesday, March 8 by Credit Suisse. The firm earned “Buy” rating on Wednesday, November 8 by Stifel Nicolaus. The firm has “Buy” rating given on Thursday, February 2 by Needham. The stock of Brooks Automation, Inc. (NASDAQ:BRKS) has “Buy” rating given on Friday, November 6 by Needham. FBR Capital maintained Brooks Automation, Inc. (NASDAQ:BRKS) on Monday, November 13 with “Buy” rating. See Brooks Automation, Inc. (NASDAQ:BRKS) latest ratings:

13/11/2017 Broker: FBR Capital Rating: Buy New Target: $34.0 Maintain
10/11/2017 Broker: Citigroup Rating: Buy Old Target: $31 New Target: $34 Maintain
08/11/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $32 New Target: $38 Maintain
06/11/2017 Broker: FBR Capital Rating: Buy New Target: $34.0
18/09/2017 Broker: Needham Old Rating: Buy New Rating: Hold Downgrade
07/08/2017 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Old Target: $22 New Target: $32 Upgrade
03/08/2017 Broker: Credit Suisse Rating: Neutral Old Target: $25.5 New Target: $26 Maintain
03/08/2017 Broker: B. Riley & Co Rating: Buy New Target: $34.0000 Maintain

Investors sentiment decreased to 1.43 in Q2 2017. Its down 0.38, from 1.81 in 2017Q1. It worsened, as 21 investors sold Brooks Automation, Inc. shares while 61 reduced holdings. 51 funds opened positions while 66 raised stakes. 63.04 million shares or 0.41% less from 63.30 million shares in 2017Q1 were reported. Texas-based Barrow Hanley Mewhinney Strauss Limited Liability Company has invested 0.16% in Brooks Automation, Inc. (NASDAQ:BRKS). Rice Hall James Assocs Lc accumulated 139,369 shares. Maryland-based Profund Ltd has invested 0.01% in Brooks Automation, Inc. (NASDAQ:BRKS). Robeco Institutional Asset Mgmt Bv, Netherlands-based fund reported 13,863 shares. Wellington Mngmt Ltd Liability Partnership owns 795,245 shares for 0% of their portfolio. 305,066 were reported by Martingale Asset Management L P. Commercial Bank Of America De reported 186,646 shares. Panagora Asset Inc owns 122,511 shares for 0.01% of their portfolio. Ameritas Invest Ptnrs Incorporated accumulated 6,038 shares. Moreover, De Burlo Grp Inc has 0.53% invested in Brooks Automation, Inc. (NASDAQ:BRKS) for 109,900 shares. Usa Fincl Portformulas Corp holds 0.2% or 38,960 shares. Bank Of Ny Mellon accumulated 0.02% or 2.56M shares. Ny State Teachers Retirement Systems invested in 156,127 shares or 0.01% of the stock. Castleark Mgmt Lc has 0.22% invested in Brooks Automation, Inc. (NASDAQ:BRKS) for 317,333 shares. Hanseatic stated it has 0% of its portfolio in Brooks Automation, Inc. (NASDAQ:BRKS).

The stock increased 3.20% or $0.74 during the last trading session, reaching $23.89. About 1.05 million shares traded or 13.85% up from the average. Brooks Automation, Inc. (NASDAQ:BRKS) has risen 181.96% since December 8, 2016 and is uptrending. It has outperformed by 165.26% the S&P500.

Brooks Automation, Inc. provides automation and cryogenic solutions for various applications and markets. The company has market cap of $1.67 billion. It operates through two divisions, Brooks Semiconductor Solutions Group and Brooks Life Science Systems. It has a 26.84 P/E ratio. The Brooks Semiconductor Solutions Group segment offers critical automated transport, vacuum, and contamination controls solutions and services.

Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.30, from 1.29 in 2017Q1. It increased, as 12 investors sold Enzo Biochem, Inc. shares while 27 reduced holdings. 28 funds opened positions while 34 raised stakes. 25.22 million shares or 2.12% more from 24.70 million shares in 2017Q1 were reported. Bogle Investment Mgmt L P De has invested 0.09% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). First Light Asset Limited Liability accumulated 1.49% or 403,082 shares. Creative Planning reported 31 shares. California State Teachers Retirement stated it has 0% in Enzo Biochem, Inc. (NYSE:ENZ). Susquehanna Intll Grp Ltd Liability Partnership, a Pennsylvania-based fund reported 66,452 shares. Cubist Systematic Strategies Limited Liability Corp owns 0.01% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 11,210 shares. 32,834 are owned by Barclays Public Ltd Co. Art Advsr Limited Liability stated it has 0.01% in Enzo Biochem, Inc. (NYSE:ENZ). Bnp Paribas Arbitrage Sa holds 4,197 shares or 0% of its portfolio. Northwestern Mutual Wealth Mgmt has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Advisory Ntwk Ltd Liability Co holds 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ) for 2,753 shares. Manufacturers Life Insurance The has 34,404 shares. Ubs Asset Mngmt Americas Inc invested in 0% or 356 shares. Deutsche Financial Bank Ag holds 0% or 72,347 shares in its portfolio. Walleye Trading Limited Company owns 5,036 shares or 0% of their US portfolio.

Since June 13, 2017, it had 0 insider buys, and 1 insider sale for $160,054 activity. O’Brien James Michael also sold $160,054 worth of Enzo Biochem, Inc. (NYSE:ENZ) shares.

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $446.26 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: